Managing Director, FasterCures, Milken Institute Health
Sung Hee Choe is the managing director on the FasterCures team at the Milken Institute. She oversees the programmatic portfolio and is responsible for day-to-day operations.
Esther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
Cell and gene therapies are a new category of medicines transforming how we treat and potentially cure disease. Both cell and gene therapies seek to modify genetic material to fight disease. Cell therapies involve cultivating or modifying cells outside the body before injecting them into a patient. Gene therapies use genetic material to manipulate the expression of a gene or alter the properties of an individual’s cells.
Today, seven cell and gene therapies are approved for marketing in the US and fewer than 10 are approved in Europe. Dozens of new cell and gene therapies are expected to become available in the US in the coming years. According to recent research, more than 1,000 cell and gene therapies are currently in development, with 50–75 therapies expected to be approved in the US by 2030.
In response to this growing pipeline and the hope these therapies offer, FasterCures convened roundtables and discussions to bring to light the unique regulatory and access considerations posed by cell and gene therapies. On November 3, 2021, FasterCures brought together its stakeholder community, along with Peter Marks, director of CBER at FDA, in a virtual roundtable. The goals of the roundtable included taking stock of the current status of cell and gene therapies given the disruptions caused by the COVID-19 pandemic, and identifying opportunities for collective engagement in 2022.
This report summarizes the key takeaways from the November 3 roundtable, and considers the developments that will take place in cell and gene therapies in 2022.
LOS ANGELES—More than 4,000 international leaders in business, government, science, philanthropy, academia, arts, and culture will meet in California for the 21 st Milken Institute Global Conference beginning April 29, 2018. Confirmed...
Publicly available resource monitors the development of therapies to treat and prevent disease WASHINGTON, March 18, 2020 — The Milken Institute is launching a resource to help the public and policymakers track progress in the development...
Investing in the intersection of food and healthcare is critical to achieving nutrition equity. Feeding Change submitted a letter informed by the Food Is Medicine Task Force that provides comments to inform the national strategy for the...
Senior Director, Feeding Change, Milken Institute Health
Holly Freishtat is the senior director of Feeding Change at the Milken Institute. She is an experienced director, transformative leader, and strategist with a 20-year track record developing and implementing food system policies and programs.
August 1, 2023 (SINGAPORE) - The annual Milken Institute Asia Summit, taking place from September 13 – 15, will convene regional and global leaders to discuss a wide range of issues and challenges shaping the Asia Pacific region including...
Associate Director, Milken Institute International
Yeen Chee Chong is an associate director for Milken Institute International. Based in Singapore, he oversees and manages strategic communications with a wide range of global and regional media publications and partners. Chong works closely with colleagues in both Asia and the United States on planning and implementing global public relations and social media campaigns.
Each Venture Philanthropy transaction involves numerous complicated issues: governance, intellectual property ownership and licensing, termination, indemnification, and publication, among others, but the issue that encompasses the most...
Did the United Nations' ambitious Millennium Development Goals improve the health of people in emerging regions of the world? In this paper, a discussion of the precursors of higher living standards and better health, Milken Institute...
Good mental health is critical to overall health and well-being, but a cycle of almost endless stressors, stigma, and systemic barriers to accessing quality care have brought America’s collective mental health to a breaking point. In 2018...
The Financial Innovations Labs® and FasterCures teams have collaborated on a project to identify new models for financing the antimicrobial resistant antibiotic pipeline. These past 18 months have demonstrated how consequential public...
If the objective of biomedical research is to spur innovation to create healthier communities, extend life, and more effectively treat or cure disease, then persistent inequities run counter to that goal and create unnecessary barriers to...
June 24, 2024 (Washington, DC)— Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available. Yet, these lifesaving treatments are often difficult or impossible...
Paul Guequierre is the director of strategic communications. In this role, he works to increase the profile of Milken Institute in the media, raise the visibility of issues important to the organization and its stakeholders, and expand the Institute's digital presence.
The FasterCures team at the Milken Institute is honored to provide its response to the Request for Comments on Optimizing the Food and Drug Administration’s Use of and Processes for Advisory Committees; Public Meeting; Request for Comments...
Esther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
FasterCures has long been at the forefront of shaping the national focus on biomedical innovation, with a singular goal of saving lives by accelerating scientific advances for all patients. FasterCures has been instrumental in advocating...
